Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits

Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.